Literature DB >> 15962838

Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue.

Krishnamurthy P Gudehithlu1, Naila Ahmed, Henry Wu, Natalia O Litbarg, Sandra L Garber, Jose A L Arruda, George Dunea, Ashok K Singh.   

Abstract

Vascular endothelial growth factor (VEGF) is a potent growth factor that is indispensable for the development of blood vessels in the fetus and for wound healing in adults. VEGF likely plays a role in maintaining the blood vessels once they have been formed. It is not clear, however, whether a low tissue VEGF (caused either by disease or by systemic administration of VEGF antagonists) can cause abnormalities in preexisting blood vessels, especially of wound tissue that requires high local levels of VEGF for healing. The present study investigated the effect of VEGF antagonism on blood vessels of foreign-body granulomas (a model of wound-healing tissue). Granulomas were induced by implanting perforated polyvinyl tubes into the subcutaneous tissue of rats and allowed to develop for 14 days, at which time the implanted tubes were completely encapsulated by the subcutaneous tissue. The encapsulated granulomas consisted of 3 distinct histological layers, of which the middle layer was well perfused by a rich supply of microvessels. Morphologically, the granuloma remained "stable" after developing for 14 days. At 1 week, VEGF levels in the granuloma fluid, which is in equilibrium with the interstitial fluid, were 25 times higher than in the plasma. VEGF levels in the granuloma fluid continued to increase for up to 3 weeks, reflecting the high dependence of the wound tissue on ambient VEGF levels. After injection of the VEGF receptor antagonist in the fully formed granuloma, the preexisting blood vessels in the middle layer regressed and underwent apoptosis, accompanied by expansion of the extracellular matrix (predominately collagen I) into areas normally devoid of matrix. We conclude that wound tissue is sensitive to ambient VEGF levels, and that a low VEGF condition resulting from VEGF receptor antagonism can disrupt the healing of wound tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962838     DOI: 10.1016/j.lab.2005.02.007

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  Autologous tissue patch rich in stem cells created in the subcutaneous tissue.

Authors:  Ignacio Garcia-Gomez; Krishnamurthy P Gudehithlu; Jose A L Arruda; Ashok K Singh
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

2.  Plasma levels of angiopoietin-like protein 4 (ANGPTL4) are significantly lower preoperatively in colorectal cancer patients than in cancer-free patients and are further decreased during the first month after minimally invasive colorectal resection.

Authors:  H M C Shantha Kumara; Daniel Kirchoff; Sajith A Herath; Joon Ho Jang; Xiaohong Yan; Michael Grieco; Vesna Cekic; Richard L Whelan
Journal:  Surg Endosc       Date:  2012-05-02       Impact factor: 4.584

3.  Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.

Authors:  H M C Shantha Kumara; A Hoffman; I Y Kim; D Feingold; N Dujovny; M Kalady; M Kallady; M Luchtefeld; R L Whelan
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

4.  Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.

Authors:  A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan
Journal:  Surg Endosc       Date:  2008-01-18       Impact factor: 4.584

5.  Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Helmut Teschler; Lonny Yarmus; Konstantinos Zarogoulidis; Lutz Freitag
Journal:  J Mol Genet Med       Date:  2013-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.